Importantly, although symptoms levels appear to reduce as people grow older there are parallel changes among control groups; so that significant case-control differences are retained [ 14].
For each hub, t-values related to voxels showing a significant post-NS/post-SC difference were retained (both for delta and theta).
Moreover, the mean value for Natalizumab-treated patients was still higher, but no longer differed significantly from healthy control CRT levels, while significant differences (p<0.05) were retained between non-Natalizumab samples and controls.
In contrast, significant differences were observed in their reductive activities: EhPDICC/SS retained about 60%, whilst EhPDISS/CC roughly retained 20%.
No significant differences were found between the drop out and retained groups and thus any bias from sample attrition is likely to be minor.
No statistically significant differences were found between those excluded from the analysis and those retained (data not shown).
No significant differences were observed.
In osteoblasts no significant differences were detectable.
Statistically significant differences were assumed when p<0.05.
Statistically significant differences were determined at P<0.05.
